Pink Sheet covers compounding and the "green list"

Citeline's Pink Sheet blog, which covers regulations, ran a post explaining compounding pharmacies' perspective on the FDA's new "green list" of GLP-1 API manufacturers. In case you somehow missed it, the green list doesn't affect legit compounders — those rarely if ever deal with API manufacturers, instead going through (FDA-licensed) wholesalers. 

The Sheet even included quotes from our own Scott Brunner, who explained how the green list actually makes it clear that compounding pharmacies' APIs are, in fact, the same as those used by big manufacturers: “At no point in the shortage of GLP-1s, and in the aftermath of the GLP-1 shortage, has FDA raised any concerns about the quality of the active pharmaceutical ingredient [that legitimate compounding pharmacies were using].”